To determine the effect of BRAF inhibition on the metabolism of human melanoma cells, we performed in vitro 1H MRS at 9.4T on four melanoma cell lines treated with dabrafenib, a wild-type (WM3918), a resistance mutant-type (WM983BR), and two sensitive mutant-types (WM983B and DB-1). Here, BRAF is linked to melanoma.